Clinical Studies and Case Reports

On this site you will find clinical studies with cannabis or single cannabinoids in different diseases and case reports on the use of cannabis by patients.
You may search for diseases (indications), authors, medication, study design (controlled study, open trial, case report etc.) and other criteria.




[Back to Overview]  [IACM Homepage]

TitleCannabis reduces opioid dose in the treatment of chronic non-cancer pain.
Author(s)Lynch ME, Clark AJ.
Journal, Volume, IssueJ Pain Symptom Manage. 2003 Jun;25(6):496-8.
Major outcome(s)Improvement in pain, spasticity, bladder spasm, and sleep.
IndicationPainAbstract
MedicationCannabis

No abstract available.
First of three case reports:
A 47-year-old woman with a ten-year history of chronic progressive multiple sclerosis (MS) head headache, multisite joint pain, bladder spasm, and leg spasticity. Ambulation was significantly compromised by the joint pain and leg spasticity. She was wheelchair dependent, and also suffered from severe insomnia and fatigue, which she attributed to the combination of pain, bladder spasm, and leg spasticity. Physical examination revealed paraparesis, weakness in the left upper extremity, tremor involving both hands, intranuclear ophthalmoplegia and l’Hermitte’s sign. Previous treatment included steroids, physiotherapy, acupuncture, interdisciplinary pain management, intramuscular injections of botulinum toxin, amitritryptiline, fluoxetine, amantadine, acetaminophen with codeine, oxycodone, nonsteroidal anti-inflammatory drugs (NSAIDS), and baclofen. The patients’ medications prior to access to smoked marijuana consisted of long-acting morphine 75 mg per day, tizanidine 24 mg per day, and sertraline 150 mg at bedtime. In spite of these treatments, the patient did not obtain adequate control of her pain, spasticity, or sleep.
The patient received permission for access to smoked marijuana and began to use a dose of 2-4 puffs of smoked marijuana at bedtime on a regular basis. Over the next six months, the morphine was reduced to 45 mg per day, tizanidine to 6 mg once per day, and setraline to between 100 mg and 150 mg at bedtime. The patient reported improvement in pain, spasticity, bladder spasm, and sleep. The patient denied any adverse side effects, other than she felt somewhat “high” if she smoked more than 4 puffs per dose. She was able to adjust the dose so that this did not occur. The patient received legal access in the autumn of 2000 and continues to use marijuana.

Route(s)Inhalation
Dose(s)
Duration (days)
Participants3
DesignUncontrolled case report
Type of publicationMedical journal
Address of author(s)Queen Elizabeth II Health Sciences Center, Dalhousie University, Halifax, Nova Scotia, Canada
Full texthttp://www.sciencedirect.com/science?_ob=ArticleURL&_udi=B6T8R-48NRFFY-4&_coverDate=06%2F30%2F2003&_alid=160956753&_rdoc=1&_fmt=&_orig=search&_qd=1&_cdi=5093&_sort=d&view=c&_acct=C000050221&_version=1&_urlVersion=0&_userid=10&md5=492adfbbcee3afff7af9257f0

[Back to Overview]  [IACM Homepage]


up